Technical Analysis for CGON - CG Oncology, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| NR7 | Range Contraction | 13.73% | |
| Inside Day | Range Contraction | 13.73% | |
| Oversold Stochastic | Weakness | 13.73% |
| Alert | Time |
|---|---|
| Rose Above 50 DMA | 1 day ago |
| Up 2 ATRs | 1 day ago |
| 50 DMA Resistance | 1 day ago |
| Up 10% | 1 day ago |
| Up 5% | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Virotherapy Immunotherapies Oncolytic Virus
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Virotherapy Immunotherapies Oncolytic Virus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 50.23 |
| 52 Week Low | 28.55 |
| Average Volume | 522,294 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 40.25 |
| 20-Day Moving Average | 37.92 |
| 10-Day Moving Average | 36.43 |
| Average True Range | 2.48 |
| RSI (14) | 58.16 |
| ADX | 16.73 |
| +DI | 26.97 |
| -DI | 22.34 |
| Chandelier Exit (Long, 3 ATRs) | 37.75 |
| Chandelier Exit (Short, 3 ATRs) | 40.84 |
| Upper Bollinger Bands | 42.31 |
| Lower Bollinger Band | 33.53 |
| Percent B (%b) | 0.85 |
| BandWidth | 23.15 |
| MACD Line | -0.76 |
| MACD Signal Line | -0.95 |
| MACD Histogram | 0.1863 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 48.06 | ||||
| Resistance 3 (R3) | 47.34 | 44.27 | 46.88 | ||
| Resistance 2 (R2) | 44.27 | 42.47 | 44.63 | 46.49 | |
| Resistance 1 (R1) | 42.64 | 41.36 | 43.45 | 43.35 | 46.10 |
| Pivot Point | 39.57 | 39.57 | 39.97 | 39.92 | 39.57 |
| Support 1 (S1) | 37.93 | 37.77 | 38.75 | 38.65 | 35.90 |
| Support 2 (S2) | 34.86 | 36.66 | 35.22 | 35.51 | |
| Support 3 (S3) | 33.23 | 34.86 | 35.12 | ||
| Support 4 (S4) | 33.94 |
